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Apa I polymorphism in the vitamin D receptor gene may affect the
parathyroid response in Japanese with end-stage renal disease. Vitamin
D [1,25(OH)2D3] plays a key role in the pathogenesis of secondary
hyperparathyroidism. A polymorphism in the vitamin D receptor (VDR)
gene is reported to be involved in bone mineral density and the serum
level of intact-osteocalcin (i-OC) in patients with osteoporosis. We
investigated the relationship between VDR gene polymorphisms and the
levels of intact PTH (i-PTH) and i-OC in 129 Japanese patients with
end-stage renal disease (ESRD). The VDR gene sequences were PCR-
amplified, and the product was cleaved with the restriction enzymes Bsm
I and Apa I. Undigested alleles were designated as B and A, and the
digested alleles as b and a, respectively. The frequencies for the Bsm I
polymorphism were 0.0% BB, 19.4% Bb, and 80.6% bb, while those for
Apa I polymorphism were 14.2% AA, 47.2% Aa, and 38.6% aa. The Bsm
I polymorphism of VDR was greatly biased in Japanese people. The
i-PTH level in the aa group was about twice as high as those in the both
AA group and Aa group (P # 0.04). The i-OC concentrations in the aa
group was also approximately double those in both the AA group and Aa
group (P # 0.03). In contrast, no significant differences in age, duration of
dialysis, male/female ratio, or the incidence of diabetic nephropathy were
observed among these three groups. On the other hand, there was no
significant differences in i-PTH and i-OC between the Bb and bb groups.
These results suggest that VDR gene polymorphisms can affect parathy-
roid response in ESRD patients, and the Apa I polymorphism is more
informative in Japanese patients than the Bsm I polymorphism. The VDR
a gene allele may define the pathogenesis of secondary hyperparathyroid-
ism and of high turnover bone disease in patients with ESRD.
Abnormal metabolism of calcium is involved in pathogenesis of
secondary hyperparathyroidism and high turnover bone disease in
patients with end-stage renal disease (ESRD) [1–4]. Vitamin D
[1,25(OH)2D3] plays a key role in the progression of secondary
hyperparathyroidism through the vitamin D receptor (VDR) [5].
Vitamin D also stimulates intestinal Ca21 absorption and raises
the serum Ca21 concentration [6]. Excess PTH in secondary
hyperparathyroidism accelerates bone turnover, causing the high
turnover bone disease known as osteitis fibrosa [7]. Intact osteo-
calcin (i-OC), produced and secreted from osteoblast, is thought
to be a good marker of bone turnover in patients with ESRD
undergoing regular renal replacement therapy [8].
It has been reported that a VDR gene polymorphism, which
was detected using the restriction enzyme Bsm I, is involved in
bone mass and bone turnover in osteoporotic patients [9–13]. In
addition, an association between VDR gene polymorphisms and
bone mineral density has been observed in the Japanese popula-
tion [14, 15]. However, the frequency of these genotypes detected
in Asian (Japanese and Korean) subjects using the same restric-
tion enzyme differs markedly from that in Western subjects
[10–13]. To determine whether the VDR gene polymorphism is
associated with bone turnover in Japanese ESRD patients, we
assayed the levels of intact PTH and i-OC in uremic Japanese
patients with the Bsm I site polymorphism and with a second
polymorphism at the Apa I site in the same intron.
METHODS
A total of 129 Japanese patients with ESRD (47 women and 82
men), who were undergoing regular renal replacement therapy at
the Toranomon Hospital Kidney Center, were selected as sub-
jects. Their mean age was 60.6 6 1.2 years and the mean duration
of dialysis was 9.2 6 0.6 years. Only patients aged about 60 were
selected and analyzed in order to exclude age affects. The subjects
included 48 ESRD patients with diabetic nephropathy as the
original kidney disease. Informed consent was provided by each
subject. Genomic DNA was extracted from peripheral white
blood cells. The VDR gene sequences were amplified using the
polymerase chain reaction (PCR). The Bsm I polymorphism was
detected using one primer originating in exon 7 (primer 1:
59-CAACCAAGACTACAAGTACCGCGTCAGTGA-39) and a
second in intron 8 (primer 2: 59-AACCAGCGGGAAGAGGT-
CAAGGG-39), which amplify an 825 base pair (bp) fragment
spanning the Bsm I site. The Apa I polymorphism was detected
using one primer in intron 8 (primer 3: 59-CAGAGCATGGA-
CAGGGAGCAAG-39) and the other in exon 9 (primer 4:
59-GCAACTCCTCATGGCTGAGGTCTCA-39) yielding a 740
bp fragment spanning the Apa I site. Each amplification was
subjected to 30 amplification cycles in a thermal cycler (PC-700;
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ASTEC, Fukuoka, Japan). Samples were digested with the respec-
tive enzyme and electrophoresed on agarose gels, and genotype
were determined from fragment lengths [14].
Blood samples taken just before each hemodialysis session were
used to measure i-PTH, i-OC, serum albumin (SAlb), calcium
(SCa), magnesium (SMg), and phosphate (SP). The i-PTH was
determined using an Allegro-intact PTH kit (Mediphysics Japan
Co., Ltd., Nishinomiya, Japan). SCa and SMg were determined by
atomic absorption spectrometry, and SP was measured by the
standard method. The corrected serum calcium (cSCa) level was
calculated by Payne’s formula [16].
Data are expressed as the mean 6 standard error of the mean
(SEM). The two-sample t-test with Welch’s correction and the
Mann-Whitney test were applied to statistical analysis between
two groups. The chi-square test, the one-way ANOVA and the
Kruskal-Wallis test were applied to statistical analysis among
three groups. Differences were considered to be significant at P ,
0.05.
RESULTS
Vitamin D receptor genotype frequencies
When patients’ DNA were assayed for the Bsm I polymor-
phism, and the results used to calculate genotype frequencies, we
observed a marked bias in genotypes in Japanese populations
(Table 1). The frequency of the bb genotype was 80%, whereas
the BB genotype was not observed at all. When polymorphisms at
the Apa I the restriction site were assayed, we observed AA, Aa,
and aa genotype frequencies of 14.2%, 47.2%, and 38.6%, respec-
tively.
Relationship between the A-allele and PTH, osteocalcin levels
and other factors
We observed significantly higher concentrations of blood i-PTH
in patients with the aa genotype (267.5 6 57.5 pg/ml) than in
patients with the AA and Aa genotypes (126.7 6 26.6 and 145.7 6
24.1 pg/ml, respectively; P , 0.04; Table 2). Similarly, the
concentrations of the i-OC levels in patients with the aa allele
(82.8 6 23.9 ng/ml) were approximately double those of patients
with the AA and Aa alleles (36.8 6 5.6 and 34.9 6 3.9 ng/ml,
respectively; P , 0.03; Table 2). However, there was no significant
difference in i-PTH and i-OC between the AA and Aa groups.
The corrected serum calcium (cSCa), obtained by correction for
the serum albumin level, serum phosphorus and serum magne-
sium, are shown in Table 2. There were no significant difference
in three electrolytes among the AA, Aa and aa genotypes. In
addition, when the three groups were analyzed with respect to
age, female/male ratio, the incidence of uremic patients with
diabetic nephropathy, and duration of dialysis, no significant
differences were observed among three genotypes (Table 3).
Relationship between the B-allele and PTH and osteocalcin
levels
There was no significant difference in i-PTH and i-OC between
patients with the Bb and bb genotypes (Fig. 1). The level of i-PTH
in patients with the Bb genotype was almost the same in patients
with the bb genotype (181.8 6 39.6 and 179.8 6 27.1 pg/ml,
respectively). The i-OC level was also quite similar level between
two genotype groups (44.7 6 7.0 and 54.2 6 11.2 ng/ml, respec-
tively).
DISCUSSION
It is known that VDR is present in parathyroid cells of not only
patients with ESRD but also in normal subjects [1, 5]. It has been
clarified that calcitriol, the ligand, is suppressing expression of
PTH mRNA and intact-PTH secretion by binding to this VDR,
independently of extracellular Ca concentration, in patients with
at least secondary hyperparathyroidism [1, 2, 4]. Also, a negative
vitamin D responsive element (nVDRE) that is the part inducing
negative regulation by calcitriol was discovered in the PTH gene
[17, 18]. Accordingly, we investigated the involvement of VDR
gene polymorphisms in secondary hyperparathyroidism and bone
turnover rate. We selected only Japanese patients as subjects in
order to provide a homogeneous ethnic group without the effects
of race. Because secondary hyperparathyroidism is easily affected
by the therapeutic strategy, (for example, vitamin D administra-
tion, dietary therapy and administration of phosphate binder), we
chose subjects treated at a single institution to ensure a uniform
therapeutic strategy.
The frequency of Caucasian patients with the BB genotype has
been reported to be about 15% [10–13]. In contrast, Lee et al
reported a BB genotype frequency of 1.4% in Koreans [19], and
others have found a BB genotype frequency in only 1 to 2% in a
large number of Japanese subjects [14, 15]. Therefore, in east
Asian populations, the distribution of VDR genotypes obtained
using Bsm I is skewed and unsuitable for analysis. However, when
we used the restriction enzyme Apa I, which also cleaves the
intron of the VDR gene between exons 8 and 9, we found a more
evenly distribution of genotypes, which at least in Japanese
subjects is more suitable for analysis. The genotype distribution
that we obtained resembled that previously reported in Japanese
subjects with osteoporosis, suggesting that this distribution is
present in the Japanese population at large [14, 15]. Tsukamoto et
al recently suggested that serum levels of PTH are low in ESRD
patients with the BB genotype in VDR gene polymorphisms by a
Bsm I cleave [20]. When we investigated the association between
the Apa I polymorphism in the VDR gene and the i-PTH level
and i-OC level in ESRD patients, we found that both a parameter
of bone turnover rate (i-OC) and the severity of secondary
hyperparathyroidism (i-PTH) were significantly higher in aa ge-
notype group than in others (AA and Aa groups).
The mechanism by which VDR gene polymorphisms affect the
parathyroid response is still obscure. Recently, a few possibilities
have been proposed. Morrison et al suggested a possibility that
differential sequences of the 39 untranslated region (39UTRs)
derived from the genotype of VDR gene polymorphism may vary
the half-life of the transcript [10]. However, their proposal
Table 1. The frequencies of VDR gene polymorphism determined by
restriction enzyme Bsm I and Apa I cleavage
Bsm I BB Bb bb Total
N 0 (0.0%) 25 (19.4%) 104 (80.6%) 129 (100%)
Apa I AA Aa aa Total
N 18 (14.2%) 60 (47.2%) 49 (38.6%) 127 (100%)
Undigested alleles were designated as B and A, and the digested alleles
as b and a.
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remained a hypothesis. More recently, Ebihara et al indicated that
new VDR isoform translated by a new exon derived from intron
8 with an alternative splicing process may negatively modulate the
vitamin D signaling pathway in rats [21]. Since exons 7 to 9 code
the hormone binding site, this VDR isoform cannot normally
transduce signals of calcitriol as a ligand, and possible generation
of phenotypic differences is indicated. It is highly probable that
the same type of change could occur in human VDR gene, and the
relationship between VDR gene polymorphisms and phenotypes
may be explained by the difference in the intron. In the case of
vitamin D resistant rickets, in addition, Hawa et al demonstrated
that exon skipping occurred during RNA processing, probably
owing to position 15 in intron 4, where frameshift took place, and
the receptor function of VDR greatly decreased [22]. It would not
be not surprising if changes in the VDR gene polymorphism site
in Intron 8 occurred in a similar manner, and possible skipping in
exon 8 cannot be excluded. If this is the case, a newly translated
and synthesized VDR could be deficient in the ligand binding site
and exhibit hypofunction, and then the relationship between VDR
gene polymorphisms and the phenotype may be able to be
explained.
Carling and his collaborators showed that the difference in the
mechanism of extracellular calcium sensing by parathyroid cells
depends on the genotype of VDR polymorphism in primary
hyperparathyroidism [23]. This result is understandable in consid-
eration of the articles describing that expression of calcium
sensing protein is related not to calcium but vitamin D status [24],
and that the sensitivity of parathyroid cells to extracellular calcium
is restored by administration of calcitriol [25]. They reported that
serum PTH level was high in the aa genotype of VDR gene
polymorphism, and the PTH in the aa group was not easily
lowered by raising the extracellular calcium level. The results are
quite compatible with our present results. The sensitivity of
parathyroid cells for extracellular calcium concentration may be
different among the three genotypes (AA, Aa, aa) of VDR
polymorphism. In addition, the decreased VDR density in para-
thyroid glands with refractory secondary hyperparathyroidism has
been reported in chronic uremic patients [4]. The possibility of the
difference in VDR density among VDR gene genotypes may not
be able to be discarded. However, Mocharla et al have shown that
Bsm I polymorphism of VDR did not affect the abundance of the
VDR mRNA in peripheral blood mononuclear cells [26]. There-
fore, it is unlikely that VDR gene polymorphism induces a
difference in parathyroid function by means of the mechanism of
changing VDR density.
Matsuyama et al have hypothesized that polymorphisms in this
gene may be associated with the bone turnover and bone mass
after treatment with 1a(OH)D3 administration [27]. A genetic
effect has been shown by Howard et al, who demonstrated that
vitamin D receptor gene alleles may influence the change in
serum phosphorus following vitamin D supplementation [28].















AA 18 126.7 6 26.6 36.8 6 5.6 4.6 6 0.1 5.4 6 0.3 3.2 6 0.3
Aa 60 145.7 6 24.1 34.9 6 3.9 4.7 6 0.1 5.6 6 0.2 3.5 6 0.2
aa 49 267.5 6 57.2 82.8 6 23.9 4.6 6 0.1 5.4 6 0.2 3.6 6 0.6
Probability P , 0.04 P , 0.03 NS NS NS
Data are expressed as the mean 6 standard error of the mean (SEM). Abbreviations are: VDR, vitamin D receptor; PTH, parathyroid hormone; OC,
intact-osteocalcin; NS, no significant difference.








AA 18 60.7 6 2.1 6/12 7/18 9.2 6 1.1
Aa 60 62.2 6 2.0 25/35 26/60 8.7 6 0.9
aa 49 60.5 6 2.0 17/32 15/49 8.8 6 1.1
Probability NS NS NS NS
Data are expressed as the mean 6 standard error of the mean (SEM). Abbreviations are: DN, uremic patients with diabetic nephropathy as original

























Fig. 1. Levels of intact-parathyroid hormone (i-PTH) and intact-osteo-
calcin (i-OC) in the Bb and bb genotype groups with ESRD patients. The
distribution of polymorphism of VDR cleaved with Bsm I enzyme in
Japanese people was greatly biased. No Japanese ESRD patient showed
the BB genotype of VDR gene. The i-PTH and i-OC concentrations in the
Bb group were similar in the bb group. There were no significant
differences in i-PTH and i-OC between the two groups.
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Serum levels of phosphorus are known to be an affecting factor to
alter the PTH levels independently of vitamin D and Ca in ESRD
patients [29–32]. It has also been suggested that the calcemic
response to dietary Ca intake may be related to the VDR
genotype [33]. All of these findings strongly suggest that the VDR
gene polymorphisms may affect the parathyroid response via
therapeutic procedure in hyperparathyroidism patients. The se-
rum calcium level is well known to be a major regulatory factor on
parathyroid function [5]. Age, diabetes mellitus, duration of
dialysis and gender are also known factors that can regulate the
parathyroid response in patients with secondary hyperparathy-
roidism [34–37]. In this study, however, we found no significant
differences in these factors including serum calcium and phospho-
rus among the three group (AA, Aa, aa), suggesting that the effect
associated with VDR gene polymorphism may be independent of
these factors.
We have shown a negative association between the [A] allele
and the progression of secondary hyperparathyroidism. These
results cannot indicate whether the progression is inhibited by the
presence of this allele or accelerated by its absence. However, we
found that secondary hyperparathyroidism was mild in patients
with the AA and Aa genotypes. So far, the BB genotype has also
been shown to be associated with mild disease [38]. Both the
incidence and severity of primary hyperparathyroidism were
found to be high in patients with the bb genotype [39]. These
findings suggest that parathyroid function is stimulated in patients
with ESRD who exhibit either the [b] or [a] allele.
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APPENDIX
Abbreviations used in this article are: 1, (OH)2D3, vitamin D; VDR,
vitamin D receptor, i-OC, intact-osteocalcin; i-PTH, intact parathyroid
hormone; ESRD, end-stage renal disease; PCR, polymerase chain reac-
tion; SAlb, serum albumin; SCa, serum calcium; SMg, serum magnesium; SP,
serum phosphate; nVDRE, negative vitamin D responsive element.
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